RT Journal Article
T1 Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients
A1 Rivero-Juarez, Antonio
A1 Vallejo, Nicolau
A1 Lopez-Lopez, Pedro
A1 Díaz-Mareque, Ana Isabel
A1 Frias, Mario
A1 Vallejo, Aldara
A1 Caballero-Gómez, Javier
A1 Rodríguez-Velasco, María
A1 Molina, Esther
A1 Aguilera, Antonio
K1 HEV
K1 Treatment
K1 Zoonoses
K1 Ribavirin
K1 Transplant
K1 Virus de la hepatitis E
K1 Terapéutica
K1 Zoonosis
K1 Ribavirina
K1 Trasplantes
AB The hepatitis E virus (HEV) is the major cause of acute hepatitis of viral origin worldwide. Despite its usual course as an asymptomatic self-limited hepatitis, there are highly susceptible populations, such as those with underlying immunosuppression, which could develop chronic hepatitis. In this situation, implementation of therapy is mandatory in the sense to facilitate viral clearance. Currently, there are no specific drugs approved for HEV infection, but ribavirin (RBV), the drug of choice, is used for off-label treatment. Here, we present two cases of chronic HEV infection in transplant patients, reviewing and discussing the therapeutic approach available in the literature. The use of RBV for the treatment of an HEV infection in organ transplant patients seems to be effective. The recommendation of 12 weeks of therapy is adequate in terms of efficacy. Nevertheless, there are important issues that urgently need to be assessed, such as optimal duration of therapy and drug dosage.
PB MDPI
YR 2019
FD 2019-12-26
LK http://hdl.handle.net/10668/3849
UL http://hdl.handle.net/10668/3849
LA en
NO Rivero-Juarez A, Vallejo N, Lopez-Lopez P, Díaz-Mareque AI, Frias M, Vallejo A, et al. Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients. Microorganisms. 2019 Dec 26;8(1):51
DS RISalud
RD Apr 7, 2025